Pre-seasonal medication is recommended for cases of cedar pollinosis that are expected to manifest severe symptoms during the season, according to the standard clinical guideline in Japan. This study aims to appraise the value for money of additional costs that accompany the choice of pre-seasonal medication from payer's perspective. Based on the 12 reports of controlled clinical trials with Symptom Score (SS) and Medication Score (MS) comparing pre-seasonal medication with intra-seasonal symptomatic medication, 15 incremental cost-eŠectiveness ratios (ICERs) and 4 integrated ICERs of each group of targeted agents are estimated. Incremental eŠects are estimated by reading SS charts, and incremental costs are estimated by reading MS charts and using National Health Insurance Medical Fee Schedule and National Health Insurance Drug Price Standard. Estimated ICERs range from ¥322,195 per quality-adjusted lifeyear (QALY) to ¥57,088,063 per QALY. Integrated ICERs are: ¥1,128,286 per QALY for 2nd generation histamine H 1 receptor antagonists, ¥2,248,018 per QALY for leukotriene receptor antagonists, ¥2,692,911 per QALY for prostaglandin D 2 and thromboxane A 2 receptor antagonists, ¥1,150,943 per QALY for Th2 cytokine suppressors, and ¥1,291,341 per QALY for all agents. Pre-seasonal medication for cedar pollinosis is cost-eŠective regardless of the choice of the prophylactic agent among 2nd generation histamine H 1 receptor antagonists, leukotriene receptor antagonists, prostaglandin D 2 and thromboxane A 2 receptor antagonists, or Th2 cytokine suppressors, taking the suggested threshold of ¥5,000,000 per 1 QALY gain in Japan. The use of 2nd generation histamine H 1 receptor antagonists and Th2 cytokine suppressors are found more favourable.
INTRODUCTION
Seasonal allergic rhinitis is one of the most prevalent diseases in Japan. The pollen of Japanese cedar that scatters about in the air during the months of January to May is the most common allergen, causing 26.5％ of the nation to suŠer from cedar pollinosis every year. 1) A remarkably high morbidity raises concern about health care resources used in controlling the disease. Health care expenditure for cedar pollinosis has been estimated at ¥198,600 million 2) to ¥286,000 million 3) annually.
There are several coping strategies and treatment modalities against allergic rhinitis such as patient communication, elimination or avoidance of allergen, medication, speciˆc immunotherapy, and surgical treatment. According to the standard clinical guideline, 4) pre-seasonal oral medication is recommended for cases of cedar pollinosis that are expected to manifest severe symptoms during the season. However, whereas better clinical outcomes are expected, taking pre-seasonal medication for prophylaxis implies a heavier total dose over the season compared to intraseasonal symptomatic medication.
From the viewpoint of health economics, it is imperative to appraise the value for money of additional costs that accompany pre-seasonal medication. Therefore, we carry out a cost-eŠective analysis of choosing pre-seasonal medication instead of symptomatic medication in treating cedar pollinosis. The results should inform us whether the choice of preseasonal medication is justiˆable as an e‹cient use of nite resources for health care. It would contribute to realise the e‹cient management of the disease, as well as deepen our understanding of resource implications of preventive care.
MATERIALS AND METHODS
We conduct a cost-eŠectiveness analysis from the payer's perspective based on the reports of clinical tri- Comparison We compare the choice of preseasonal medication instead of intra-seasonal symptomatic medication with the incremental cost-eŠective-ness ratio (ICER).
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Controlled Clinical Trials
We carry out a systematic and deliberate literature search of electrical databases:``Japana Centra Revuo Medicina'' and`M edline'', with key words such as``allergic rhinitis'',``pollinosis'',``prophylactic'',``early phase'', or``pre-seasonal'', which produce 142 reports of controlled clinical trials of medication for cedar pollinosis. Controlled trials comparing pre-seasonal oral medication with intra-seasonal symptomatic oral medication are included in our analysis if the results are reported in a form of Symptom Score (SS) and Medication Score/Symptom-Medication Score (MS/ SMS) deˆned in the latest Japanese Guideline, 4) since SS corresponds to the clinical outcomes or MS/SMS to the health care resource use. (1994) and earlier, in which SS and MS/SMS are diŠerent from one in the latest Japanese guideline ver. 6 (2009) are excluded, since we plan to use SS/MS/ SMS in our outcomes estimation and costing. Twenty six trials comparing between agents of pre-seasonal medication or between agents of intra-seasonal symptomatic medication are excluded, since these comparisons are not under our consideration. Four trials of nasal drops or eye drops only are excluded, since only oral medications are recommended for preseasonal medication in the guideline. Twenty seven trials not employing SS as a measure of endpoint are excluded from 56 remained trials. Sixteen trials are further excluded, because presented results are not su‹cient for our further analysis. Finally, the exclusion of duplicated publication results in the inclusion of 12 trials reports into this study.
The use of SS as a measure of outcomes in the clinical study of cedar pollinosis is recommended in the guideline, 4) and it is used in half of the trials comparing pre-seasonal oral medication with intra-seasonal symptomatic oral medication (29/56: 52％). Al-
Fig. 2. Calculation of Incremental EŠect in Terms of QALYs
The right panel is an example of the result of a controlled trial presented with SS chart. Area A and area C show gains in outcomes and area B a loss by preseasonal medication. The left panel is a function converting SS to utility weights. We calculate the outcomes gain according to the deˆnition of QALYs: a sum of life years with certain levels of health related quality of life measured in utility weights. Areas A C in the right panel are measured after the conversion of SS to utility weights based on the left panel as shown in-between the panels. SS; symptom score. No. 12 though it is not shown in Fig. 1 , about half of the trials not employing SS as a measure of endpoint report sub-scores for SS such as Sneezing Fit Score, Runny Nose Score, or Nasal Congestion Score. This means three quarters of the trials use, or at least partially use, the recommended SS/MS/SMS system. Therefore, we consider that our use of SS/MS/SMS as one of the major inclusion criteria is acceptable, even though the number ofˆnally included reports, twelve, is relatively small. The rest of the trials, about a quarter of all, employ Japanese Rhino-conjunctivitis Quality of Life Questionnaire (JRQLQ), 5) MOS Short-Form 36-Item Health Survey (SF-36), 6) etc. as a measure of outcomes. Table 1 lists twelve identiˆed reports of trials. 7 18) All of them are non-randomised trials, while there is no report of trials with random assignment. The assignment of patients is subject to the timing of patients' voluntaryˆrst visit to clinics only, i.e., before or during the season, except Shimizu et al. 15) patients visiting the clinic before the season are assigned to a combined therapy,``with steroid nasal drop'' group if they were heavily symptomatic in the previous year, or otherwise to a single agent therapy,``without steroid nasal drop'' group. In Hirata et al. (2004) , 17) patients visiting the clinic for more than two weeks before the season are assigned to a``long course'' group, while those visiting less than two weeks before the season are assigned to a``short course'' group. And Hamajima et al. Seven 7 13) report the use of 2nd generation histamine H 1 receptor antagonists; two 14, 15) report leukotriene receptor antagonists; one 16) reports prostaglandin D 2 and thromboxane A 2 receptor antagonists; and two 17, 18) report Th2 cytokine suppressors as prophylactic agents. As a prior meta-analysis of the eŠectiveness of pre-seasonal medication summarises eŠect size by the type of agent, 19) we also estimate integrated ICERs for each group of targeted agent and all agents.
Outcomes Estimation SS is used for calculating incremental eŠect in terms of quality-adjusted lifeyears (QALYs). The QALY is one of the recommended measures of outcomes in cost-eŠectiveness analysis. 20) Especially, its use can be justiˆed when health related quality of life is the important outcome, such as treatment of arthritis, which is expected to have no impact on mortality. 21) In the same way, cedar pollinosis is not a lethal disease and alleviation of unpleasant symptoms is most important in the treatment. Figure 2 illustrates the calculation of incremental eŠect in terms of QALYs by reading SS charts. Patients' health states during the season measured in SS are converted into utility weights according to Tamayama et al. (2009) . 22) Outcomes gain is measured as areas between courses followed by the pre-seasonal medication group and the control group during the season.
Incremental eŠects are integrated for each group of targeted agent and all agents. Since QALYs are derived from SS chart readings, neither sample level data nor variables representing error are available, any typical statistical model of meta-analysis such as Mantel-Haenszel method, Peto method or DerSimonian-Laird method are not applicable. We calculate weighted averages based on the total numbers of samples enrolled in each study for the purpose of integration. Ninetyˆve ％ conˆdence intervals are also reported.
Costing In the context of this study, costs borne by patients or third party payers such as social insurers are considered. Direct payments to health care providers by them are calculated as costs, while the other type of opportunity costs, such as productivity losses, are left uncounted.
Amounts of health care provided to patients are estimated by reading MS/SMS charts and descriptions of treatments in the reported trials, which are supplemented with the standard treatment suggested by the guidelines at the time of trial. SMS is converted into MS using corresponding SS. Since no monetary data are reported in the 12 reports of controlled clinical trials, we separately estimate unit costs for these according to National Health Insurance Medical Fee Schedule 23) and National Health Insurance Drug Price Standard. 24) Unit costs, which are multiplied by the amounts of health care provided, are shown in Table 2 . Medical fee includes consultation and prescription, which ranges from ¥1,740 to ¥5,547 per consultation depending on the type of consultation and the prescription. For example, it includes the initial visit fee/follow up visit fee, examination fee such as speciˆc IgE test, prescription fee at clinics, and dispensing fee at pharmacies. Additionally, patients are assumed to make a weekly visit for Yamashita 25) Daily drug prices of targeted agents range from ¥126 to ¥296. Prices for additional drugs are calculated as averages of daily prices of possible agents used based on the description in the reports supplemented with the guidelines by the MS/SMS, which range from ¥53 to ¥253.
Incremental costs are integrated for each group of targeted agent and all agents in the similar way as incremental eŠects. We calculate weighted averages based on the total numbers of samples enrolled in each study. Ninetyˆve ％ conˆdence intervals are also reported.
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Since the time horizon of our analysis is one season of cedar pollinosis, which is less than half a year, both eŠects and costs are not discounted.
Sensitivity Analysis
In order to deal with the uncertainty of estimated outcomes and costs, stochastic sensitivity analyses are performed. Assuming that outcomes and costs are subject to triangle distributions, of which bases range ±30％ of the estimated value for 15 comparisons and 95％ conˆdence intervals for integrated ICERs, Monte Carlo simulations are carried out with 1,000 iterations.
EŠect of Pollen Scattering
The association between total pollen counts in the air during the season measured by Durham method and incremental costs/ incremental eŠects/ICERs are also analysed, since it is commonly known that the severity of symptoms and outcomes of treatments depend on the pollen level during the season. 13, 17, 26) 2nd generation histamine H 1 receptor antagonists and all agents are separately analysed taking the diŠerence in targeted agents into account. Table 3 shows the estimated outcomes. Incremental eŠects in terms of QALYs are consistently positive, which suggests pre-seasonal medication is more eŠective compared to intraseasonal symptomatic medication. Outcome gains range from 0.00007 to 0.00857 QALY. These are equivalent to gaining 37 minutes to 75 days of living in Costs Table 3 also shows the estimated costs. Incremental costs are consistently positive as anticipated, which suggests the pre-seasonal medication accompanies additional use of resources for health care. Additional costs range from ¥1,271 to ¥8,479 per season. Weighted averages of each group of targeted agents are: ¥3,949 for 2nd generation histamine H 1 receptor antagonists, ¥5,103 for leukotriene receptor antagonists, ¥4,452 for prostaglandin D 2 and thromboxane A 2 receptor antagonists, ¥5,490 for Th2 cytokine suppressors, and ¥4,623 for all agents.
RESULTS

Outcomes
Here, breakdowns of costs are also presented. In regards to the costs during the season, costs of the pre-medication group are lower than those of the control group, except for Yamashita 14) These suggest that the pre-seasonal medication tends to reduce resource use during the season.
Cost-eŠectiveness Figure 3 plots the results on a cost-eŠectiveness plane. A threshold line where ICER equals ¥5,000,000 per 1 QALY gain is drawn according to Shiroiwa et al. (2010) , 27) although there is no established threshold to judge cost-eŠectiveness in Japan. If we take this threshold, the integrated ICERs of 2nd generation histamine H 1 receptor antagonists, leukotriene receptor antagonists, prostaglandin D 2 and thromboxane A 2 receptor antagonists, and Th2 cytokine suppressors are all judged cost-eŠective. And the integrated ICER of all agents is also judged cost-eŠective, as well.
Stability of ICERs Table 3 shows the results of stochastic sensitivity analyses. In regards to the stability of integrated ICERs, no value of 2.5 percentiles results in cost-saving, while no value of 97.5 percentile go beyond the suggested threshold.
Pollen Counts and Incremental Costs/Incremental
EŠects/ICERs Figure 4 shows the results of correlation analyses between total pollen counts in the air during the season measured by Durham method and incremental costs/incremental eŠects/ICERs. These results suggest that the choice of pre-seasonal medication by patients and/or physicians is justiˆable as an e‹cient use ofˆnite resources for health care regardless of the choice of agent. The use of 2nd generation histamine H 1 receptor antagonists and Th2 cytokine suppressors are found more favourable than the use of the other agents from the viewpoint of health economics. The former is mainly due to lower drug costs, and the latter to larger eŠect among the agents. These results are considered stable, since ranges of ICERs resulted from stochastic sensitivity analyses do not pass beyond the threshold.
Since the suggested threshold for judging costeŠectiveness, ¥5,000,000 per 1 QALY gain, 27) is derived from a survey questioning willingness-to-pay in regards to life threatening diseases, the value may diŠer for no life threatening disease like cedar pollinosis here. However, we quote this value in this study, because no speciˆc threshold is available in the literature to date and prior cost-eŠectiveness analyses of pollinosis in developed countries use a threshold similar to ¥5,000,000 per 1 QALY gain. 28, 29) Although we include only two three-arm trials considering prescription patterns, their results imply that limiting target patients with more severe symptoms, administering heavier medication, or prolonging the duration of pre-seasonal medication would make ICERs even more favourable. However, prolonged pre-seasonal medication is not necessary to result in more favourable ICERs among the results based on two-arm trials.
Whereas the association between total pollen counts in the air during the season and outcomes of treatments is known in the literature, 13, 17, 26) no correlation was found between total pollen counts and incremental costs/incremental eŠects/ICERs. These may be due to the small number of included reports out of identiˆed controlled clinical trials by our literature search, 12 out of 142, which may have a bias.
There are some points to note as to the method employed in this study. As mentioned above, reports of trials included in this study are so limited that caution is needed in interpreting the results. Arguably, however, our inclusion criteria, reporting in SS and MS/SMS, is one approach to make the most from available knowledge to date in the literature in conducting a cost-eŠectiveness analysis under the context of this study, since SS allow us to estimate incremental eŠect in terms of QALYs exactly subject to the deˆnition. And there is no report of trial which describe more detailed resource use than MS/SMS. While it is admittable that estimation of unit costs in our costing is rough, our approach of averaging daily drug prices of possible choice of agents is a reasonably feasible one, and estimated incremental costs successfully re‰ect the diŠerence in resources used between pre-seasonal medication and symptomatic medication.
Since the signiˆcance of productivity losses related to cedar pollinosis has been pointed out, 30, 31) leaving this uncounted from our scope of costing might aŠect the results. Nevertheless, better outcomes by the choice of pre-seasonal medication imply negative incremental productivity loss. Therefore, estimated ICERs might be overestimates.
In conclusion, pre-seasonal medication for cedar pollinosis is cost-eŠective regardless of the choice of prophylactic agent among 2nd generation histamine H 1 receptor antagonists, leukotriene receptor antagonists, prostaglandin D 2 and thromboxane A 2 receptor antagonists, or Th2 cytokine suppressors.
